ArticleThe oncologist2025

Correction to: Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.